Found: 8
Select item for more details and to access through your institution.
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
- By:
- Publication type:
- Article
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
- By:
- Publication type:
- Article
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
- By:
- Publication type:
- Article
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
- By:
- Publication type:
- Article